Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-07-26
2000-04-11
Huang, Evelyn Mei
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514248, 514249, 514253, 514256, 514259, 514260, 514272, 514274, 544234, 544238, 544288, 544335, 544336, 544353, 544354, 544408, 546 98, 546101, 546110, A61K 3147, C07D22106
Patent
active
060488697
ABSTRACT:
The novel compounds of the present invention are those of structural formula I: ##STR1## or a pharmaceutically acceptable salt, ester, or stereoisomer thereof, which are inhibitors of 5.alpha.-reductase. The compounds of formula I are useful in the oral, systemic, parenteral or topical treatment of hyperandrogenic conditions. Methods of using the compounds of formula I for the treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as the treatment of prostatitis the treatment of sweat-related conditions such as apocrine gland sweating, hyperhidrosis, and hydradenitis suppurativa, the treatment of polycystic ovary syndrome, the prevention and treatment of bone loss and related diseases, and the prevention and treatment of premature labor are provided, as well as pharmaceutical compositions for the compounds of formula I.
REFERENCES:
patent: 5239075 (1993-08-01), Audia et al.
patent: 5495021 (1996-02-01), Audia et al.
patent: 5541190 (1996-07-01), Audia et al.
patent: 5550134 (1996-08-01), Audia et al.
patent: 5574160 (1996-11-01), Audia et al.
patent: 5578724 (1996-11-01), Haehl et al.
patent: 5621104 (1997-04-01), Graham et al.
patent: 5622961 (1997-04-01), Audia et al.
patent: 5622962 (1997-04-01), Audia et al.
patent: 5629007 (1997-05-01), Audia et al.
patent: 5635197 (1997-06-01), Audia et al.
patent: 5670514 (1997-09-01), Audia et al.
patent: 5719158 (1998-02-01), Durette et al.
patent: 5739137 (1998-04-01), Durette et al.
patent: 5910497 (1999-06-01), Durette et al.
Jones et al., J. Med. Chem., vol. 36 (1993), pp. 421-423, "Nonsteroidal inhibitors of human Type 1 steroid 5-alpha-reductase".
Neubauer et al., Drugs fo the Future, vol. 20 (1995), pp. 144-147, "Type 1 steroid 5-alpha-reductase inhibitor: treatment of androgenic alopecia".
Smith et al., 211th ACS Nat'l Meeting, Mar. 1996, MEDI 154, "Synthesis and 5-alpha-reductase inhibitory activity of benzoquinolinones derived from palladium mediated coupling reactions".
Bakshi et al., J. Med. Chem., vol. 37 (1994), pp. 3871-3874, "4,7beta-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azateroids as selective inhibitors of human Type I 5-alpha-reductase".
Mook et al., Tetra. Lett., vol. 36 (1995), pp. 3969-3972, "Synthesis of phenanthridin-3-one derivatives: non-Steroidal inhibitors of steroid 5-alpha-reductase".
Hartmann et al., Eur. J. Med. Chem., vol. 29 (1994), pp. 807-817, "Novel 5alpha-reductase inhibitors. Synthesis and structure-activity studies of 5-substituted 1-methyl-2-pyridones and 1-methyl-2-piperidones".
Graham et al., Abstracts of the 218th ACS Nat'l Mtg., New Orleans, LA, Aug. 22-26, 1999, MEDI 6, "Synthesis of potent nonsteroidal tricyclic Type I specific 5alpha-reductase inhibitors".
Smith et al., Bioorg. & Med. Chem. Lett., vol. 8 (1998), pp. 395-398, "Synthesis and 5alpha-reductase inhibitory activity of 8-substitued benzo[f]quinolinones derived from palladium . . . ".
Abell et al., Bioorg. & Med. Chem. Lett., vol. 4 (1994), pp. 1365-1368, "Preparative chiral HPLC separation of all possible steroisomers of LY191704 and LY266111 and their invitro inhibition . . . ".
Wikel et al., Bioorg. & Med. Chem. Lett., vol. 3 (1993), pp. 1157-1162, "Qsar study of benzoquinolinones as inhibitors of human Type 1 5-alpha-reductase".
Kennedy, J. of Chromatog. A., vol. 725 (1996), pp. 219-224, "Comparison of chiral separations on polysaccharide chiral stationary phases to an improved Pirkle phase".
Anderson et al., J. Org. Chem., vol. 63 (1998), pp. 8224-8228, "Cooperative catalyst effects in palladium -mediated cyanation reactions of aryl halides and triflates".
Audia et al., Tet. Lett., vol. 34 (1993), pp. 7001-7004, "Synthesis of the individual enantiomers of the benzoquinolinone human Type 1 steroid 5-alpha-reductase inhibitors LY191704 and LY266111".
Audia et al., Tet. Lett., vol. 37 (1996), pp. 4121-4124, "A diastereoselective tandem metalloenamine alkylation/aza-annulation of beta-tetralones expedites the synthesis of benzoquinolinones".
Aster Susan D.
Graham Donald W.
Langen Derek Von
Durette Philippe L.
Fitch Catherine D.
Huang Evelyn Mei
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Tricyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1176881